Brief: Bioarctic - Therapeutic Goods Administration Decides Not To Register Lecanemab In Australia
03/03/2025 08:15
March 3 (Reuters) - BioArctic AB BIOAb.ST: THERAPEUTIC GOODS ADMINISTRATION DECIDES NOT TO REGISTER LECANEMAB IN AUSTRALIA PARTNER EISAI IS EXPLORING OPTIONS TO ENSURE ACCESS TO LECANEMAB IN AUSTRALIA PARTNER EISAI IS CONSIDERING SEEKING REVIEW BY ADMINISTRATIVE REVIEW TRIBUNAL Source text: ID:nWkr4sFYpT Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln